FDA.reportPublic FDA data

Tavalisse 150 MG Oral Tablet

RxCUI
2044932
RxNorm name
Tavalisse 150 MG Oral Tablet
Display name
Tavalisse 150 MG Oral Tablet
Full name
Tavalisse 150 MG Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:50

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TAVALISSEFOSTAMATINIBRigel Pharmaceuticals, Inc.21149cc3-049b-43e2-b141-c9499160556c2025-11-05Warnings, Adverse reactionsExact identifier
rxcui: 2044932

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
21149cc3-049b-43e2-b141-c9499160556cTavalisse 150 MG Oral Tablet [PSN] · fostamatinib 150 MG Oral Tablet [Tavalisse] [SBD] · Tavalisse 150 MG (equivalent to 189.3 MG fostamatinib disodium) Oral Tablet [SY] · Tavalisse 150 MG Oral Tablet [SY]411These highlights do not include all the information needed to use TAVALISSE ® safely and effectively. See full prescribing information for TAVALISSE. TAVALISSE ® (fostamatinib disodium hexahydrate) tablets, for oral use Initial U.S. Approval: 201820251105